Lucid Hearing Prepares for Over-the-Counter Hearing Aid Market with Patented Technology Devices

Lucid Hearing'S Fio Hearing Aid And Charger
Lucid Hearing’S Fio Hearing Aid And Charger

Lucid Hearing, LLC, a market leader and global provider of advanced hearing technology and audio solutions, commends the Food and Drug Administration (FDA) for its efforts to give Americans expanded access to hearing solutions. The ruling as finalized by the FDA on Aug. 17 creates a new over-the-counter (OTC) category which allows hearing aids to be sold directly online and in stores to consumers without requiring a medical visit, audiogram test or prescription.

It is estimated that nearly 30 million American adults could benefit from using hearing aids. This new OTC ruling, which is expected to take effect in mid-October, applies to certain hearing aids for people aged 18 and older who have perceived mild to moderate hearing impairment.

“At Lucid Hearing we are committed to helping people hear better. This ruling aligns with our mission by encouraging more affordable and accessible hearing help while ensuring the safety and effectiveness of available hearing devices,” said Jason Kidd, President and COO of Lucid Hearing. “Thanks to the FDA, hearing healthcare will soon be opened up to millions of Americans experiencing hearing loss who have previously been unserved.”

Lucid Hearing’s OTC hearing aid offerings will be unique due to the company’s scientific and innovative pre-set programs that cover the vast majority of consumers’ hearing loss needs. This technology was developed in conjunction with a top audiology research university and is based on a comprehensive study of more than 90,000 audiograms. The company’s modern hearing devices – powered by a unique and patented sound processing technology – are discreet and can include features like Bluetooth functionality, mobile app control for customization, and high-definition channel counts for incredible clarity.

Lucid Hearing is unique in that we have been researchers and innovators in hearing health for 13 years, and we have been preparing for this ruling for quite some time now,” added Kidd. “We understand the combination of technology and science that is needed to ensure product effectiveness and safety, and we are thrilled about this FDA ruling because now so many more Americans will have options and can get help earlier in their hearing loss journey.”

The ruling allows the company to expand its portfolio with new OTC products. The devices will be for sale at national retailer partner locations without an appointment at price points well below prescription offerings. Lucid Hearing, which employs hundreds of licensed hearing professionals in more than 500 hearing aid centers nationwide, will also continue to offer consumers free hearing tests and an extensive line of prescription hearing aids. The company highly values all of its hearing professionals who are committed to offering expert medical evaluations and guidance to the many Americans who are best served through full-service prescription hearing solutions.

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy